Pioglitazone
- Generic Name
- Pioglitazone
- Brand Names
- Actoplus Met, Actos, Duetact, Incresync, Oseni, Tandemact, Pioglitazone Accord, Pioglitazone Actavis
- Drug Type
- Small Molecule
- Chemical Formula
- C19H20N2O3S
- CAS Number
- 111025-46-8
- Unique Ingredient Identifier
- X4OV71U42S
- Background
Pioglitazone is an antihyperglycemic used as an adjunct to diet, exercise, and other antidiabetic medications to manage type 2 diabetes mellitus. It is administered as a racemic mixture, though there is no pharmacologic difference between the enantiomers and they appear to interconvert in vivo with little consequence. The thiazolidinedione class of medicatio...
- Indication
Pioglitazone is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is also available in combination with metformin, glimepiride, or alogliptin for the same indication.
- Associated Conditions
- Diabetes, Diabetic Neuropathies, Type 2 Diabetes Mellitus
- Associated Therapies
- -
A Study of Pleiotropic Pioglitazone Effects on the Alcoholic Lung (APPEAL Study)
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2023-02-14
- Lead Sponsor
- Emory University
- Target Recruit Count
- 50
- Registration Number
- NCT03060772
- Locations
- 🇺🇸
Atlanta VA Medical Center, Decatur, Georgia, United States
Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)
- Conditions
- Interventions
- First Posted Date
- 2016-11-21
- Last Posted Date
- 2024-08-07
- Target Recruit Count
- 700
- Registration Number
- NCT02969798
- Locations
- 🇺🇸
The University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States
Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes Mellitus.
- First Posted Date
- 2016-11-08
- Last Posted Date
- 2018-03-07
- Lead Sponsor
- Takeda
- Target Recruit Count
- 236507
- Registration Number
- NCT02958956
Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML
- Conditions
- Interventions
- First Posted Date
- 2016-10-24
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- University Hospital Regensburg
- Target Recruit Count
- 10
- Registration Number
- NCT02942758
- Locations
- 🇩🇪
University Hospital Regensburg, Regensburg, Germany
Brown Fat Activation Study
- Conditions
- Interventions
- First Posted Date
- 2016-09-29
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Philip Kern
- Target Recruit Count
- 39
- Registration Number
- NCT02919176
- Locations
- 🇺🇸
Center for Clinical and Translational Science, Lexington, Kentucky, United States
HbA1c Variability in Type II Diabetes
- Conditions
- Interventions
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Weill Cornell Medical College in Qatar
- Target Recruit Count
- 150
- Registration Number
- NCT02879409
- Locations
- 🇶🇦
Hamad Medical Corporation, Doha, Qatar
A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC
- First Posted Date
- 2016-08-02
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- University Hospital Regensburg
- Target Recruit Count
- 86
- Registration Number
- NCT02852083
- Locations
- 🇩🇪
MVZ am Klinikum GmbH, Passau, Bavaria, Germany
🇩🇪Klinik für Innere Medizin, Homburg/Saar, Saarland, Germany
🇩🇪St. Antonius-Hospital, Eschweiler, Nordrhein-Westfalen, Germany
PPARγ Agonist Treatment for Cocaine Dependence
- Conditions
- Interventions
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2018-04-26
- Target Recruit Count
- 30
- Registration Number
- NCT02774343
- Locations
- 🇺🇸
The University of Texas Health Science Center at Houston, Houston, Texas, United States
Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)
- First Posted Date
- 2016-05-10
- Last Posted Date
- 2020-08-07
- Lead Sponsor
- Versailles Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT02767063
- Locations
- 🇫🇷
CHU Estaing, Clermont-Ferrand, France
🇫🇷Franck NICOLINI, Lyon, France
🇫🇷CHU de LIMOGES, Limoges, France
An Extension Study of PEAK Trial
- Conditions
- Interventions
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Kun-Ho Yoon
- Target Recruit Count
- 41
- Registration Number
- NCT02763007
- Locations
- 🇰🇷
Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.